Abstract CT161: A Phase II study of the polo-like kinase (PLK1) inhibitor onvansertib in combination with abiraterone (abi) and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC)
Keyword(s):
Phase Ii
◽
2012 ◽
Vol 19
(1)
◽
pp. 215-224
◽
2009 ◽
Vol 15
(22)
◽
pp. 7099-7105
◽
2020 ◽
Vol 18
(5)
◽
pp. 416-422
◽
2010 ◽
Vol 28
(15_suppl)
◽
pp. TPS246-TPS246
◽